Sequential Bilateral Lung Resection in a Patient with Mycobacterium Abscessus Lung Disease Refractory to Medical Treatment

Seung Heon Lee; Joo-Won Min; Sang-Won Um; Seon-Sook Han; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
January 2010
Yonsei Medical Journal;1/1/2010, Vol. 51 Issue 1, p141
Academic Journal
Case Study
Mycobacterium abscessus (M. abscessus) is the second most common nontuberculous mycobacteria (NTM) in South Korea. Nevertheless, the diagnosis and treatment of M. abscessus lung disease can be problematic. Surgical resection has been tried for patients with localized M abscessu.s lung disease refractory to medical treatment. Here, we report on a 25-year-old woman with M. abscessus lung disease who had been diagnosed and treated three times for pulmonary tuberculosis. She was initially diagnosed as having M. intracellulare lung disease; however, M abscessus was isolated after several months of medication. She had multiple bronchiectatic and cavitary lesions bilaterally, and M. abscessus was repeatedly isolated from her sputa despite prolonged treatment with clarithromycin, ethambutol, moxifloxacin, and amikacin. She improved only after sequential bilateral lung resection. Based on the experience with this patient, we suggest that, if medical treatment fails, surgical resection of a diseased lung should be considered even in patients with bilateral lesions.


Related Articles

  • New metered-dose inhaler for bronchospasm associated with COPD.  // Modern Medicine;Jan97, Vol. 65 Issue 1, p48 

    Reports on the US Food and Drug Administration's (FDA) approval of a combination of the anticholinergic bronchodilator ipratropium bromide and the beta2-adrenergic bronchodilator albuterol sulfate for patients with chronic obstructive pulmonary disease.

  • Respiratory remedy. R.M.D. // Cortlandt Forum;11/25/96, Vol. 9 Issue 11, p66 

    Features the use of various bronchodilators for the treatment of obstructive pulmonary diseases. Ratio of drugs to be used; Concern on the effects of atropine on the lungs.

  • Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. Baldwin, David R.; Allen, Martin B. // BMJ: British Medical Journal (International Edition);1/18/97, Vol. 314 Issue 7075, p163 

    Editorial. Describes a treatment process for acute exacerbation of chronic obstructive pulmonary disease. Use of non-invasive positive pressure ventilation; Summary of the result of the study to determine the efficacy of the treatment procedure; Predictors of success of the treatment.

  • Pulmonary medicine. Pingleton, Susan K. // JAMA: Journal of the American Medical Association;6/19/96, Vol. 275 Issue 23, p1849 

    Discusses some of the advances in therapy for chronic obstructive pulmonary disease (COPD) that have occurred in 1995. The expansion of the evaluation of medical therapy for airflow obstruction; Improvement of ventilation therapy; The evaluation of new surgical approaches for treatment of...

  • Correction: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Sethi, Sanjay; Jones, Paul W.; Theron, Marlize Schmitt; Miravitlles, Marc; Rubinstein, Ethan; Wedzicha, Jadwiga A.; Wilson, Robert // Respiratory Research;2010, Vol. 11, p88 

    A correction to the article "Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial" that was published in a previous issue is presented.

  • Moxifloxacin.  // Reactions Weekly;1/10/2009, Issue 1234, p27 

    The article describes the cases of four patients aged 52-83 years who developed severe pseudomembranous colitis after receiving moxifloxacin for pneumonia and/or chronic obstructive pulmonary disease (COPD). Information on the dosages and durations of moxifloxcin therapy is provided. Time to...

  • Pharmacological Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Ikeda, A.; Nishimura, K.; Izumi, T. // Drugs & Aging;1998, Vol. 12 Issue 2, p129 

    Exacerbations of chronic obstructive pulmonary disease (COPD) are usually treated with bronchodilator therapy, glucocorticoids and antibiotics. However, there are few experimental data on the effects of these agents in patients with acute COPD. A β-adrenoceptor agonist is usually given first...

  • Call for trial volunteers with serious respiratory diseases.  // Australian Journal of Pharmacy;Aug2010, Vol. 91 Issue 1083, p30 

    The article reports on the request in encouraging pharmacists to participate in three international studies concerning the treatment for patients with chronic obstructive pulmonary disease (COPD) in Australia.

  • Indacaterol Inhalation Powder (Arcaptaâ„¢ Neohaler). Elliott, William T.; Chan, James // Internal Medicine Alert;10/15/2011, Vol. 33 Issue 19, p149 

    An abstract related to the use of indacaterol in the treatment of chronic obstructive pulmonary disease (COPD), is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics